Display options
Cite
Zeng C, Feng X, Wang W, et al. Decreased expression of insulin-like growth factor binding protein 6 is associated with gastric adenocarcinoma prognosis. Oncol Lett. 2017;13(6):4161-4168doi: 10.3892/ol.2017.5993.
Zeng, C., Feng, X., Wang, W., Lv, L., Fang, C., Chi, L., Huang, L., & Zhou, Z. (2017). Decreased expression of insulin-like growth factor binding protein 6 is associated with gastric adenocarcinoma prognosis. Oncology letters, 13(6), 4161-4168. https://doi.org/10.3892/ol.2017.5993
Zeng, Changqing, et al. "Decreased expression of insulin-like growth factor binding protein 6 is associated with gastric adenocarcinoma prognosis." Oncology letters vol. 13,6 (2017): 4161-4168. doi: https://doi.org/10.3892/ol.2017.5993
Zeng C, Feng X, Wang W, Lv L, Fang C, Chi L, Huang L, Zhou Z. Decreased expression of insulin-like growth factor binding protein 6 is associated with gastric adenocarcinoma prognosis. Oncol Lett. 2017 Jun;13(6):4161-4168. doi: 10.3892/ol.2017.5993. Epub 2017 Apr 05. PMID: 28588703; PMCID: PMC5452904.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Jun;13(6):4161-4168. doi: 10.3892/ol.2017.5993. Epub 2017 Apr 05.

Decreased expression of insulin-like growth factor binding protein 6 is associated with gastric adenocarcinoma prognosis.

Oncology letters

Changqing Zeng, Xingyu Feng, Wei Wang, Lin Lv, Cheng Fang, Liangjie Chi, Liangxiang Huang, Zhiwei Zhou

Affiliations

  1. Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
  2. Department of Gastrointestinal Surgery, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China.
  3. Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, Guangdong 510060, P.R. China.
  4. Department of Oncology, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, P.R. China.

PMID: 28588703 PMCID: PMC5452904 DOI: 10.3892/ol.2017.5993

Abstract

The present study aimed to investigate the expression and prognostic significance of insulin-like growth factor binding protein 6 (IGFBP-6) in gastric adenocarcinoma. The expression of IGFBP-6 was examined in 263 specimens from gastric adenocarcinoma patients using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blotting and immunohistochemical (IHC) staining. The association between IGFBP-6 expression, clinicopathological factors and clinical outcomes was investigated. Akaike information criterion (AIC) and Harrell's concordance index (c-index) were used to evaluate the accuracy of the predictive prognosis. RT-qPCR and western blotting results showed that IGFBP-6 mRNA expression was lower in the tumors compared with that in adjacent non-tumor tissues. IGFBP-6 showed significantly decreased expression in 170 out of 263 patients based on IHC data and this was associated with a larger tumor size (P<0.001) and poorly-differentiated adenocarcinoma (P=0.001), as well as with palliative gastrectomy (P=0.015). Additionally, decreased expression of IGFBP-6 was associated with stage T3/4a/4b disease and lymph node-positive metastasis (P<0.001). The association between decreased expression and a poor prognosis was revealed by Kaplan-Meier curves. Cox regression model identified IGFBP-6 as an independent prognostic factor. The prognostic value of the model with IGFBP-6 expression (AIC, 924.881; c-index, 0.878) was superior to that without IGFBP-6 expression (AIC, 947.164; c-index, 0.825). In conclusion, IGFBP-6 involves the development and progression of gastric adenocarcinoma, and its decreased expression predicts poor clinical outcomes.

Keywords: expression; gastric carcinoma; insulin-like growth factor binding protein 6; prognosis

References

  1. Clin Cancer Res. 2006 Feb 15;12(4):1208-14 - PubMed
  2. Pathol Int. 2009 Mar;59(3):121-36 - PubMed
  3. Breast Cancer Res Treat. 1992;22(1):21-9 - PubMed
  4. Horm Metab Res. 2003 Nov-Dec;35(11-12):778-85 - PubMed
  5. Mol Cell Biol. 1999 May;19(5):3278-88 - PubMed
  6. Int J Cancer. 2001 Dec 1;94(5):645-51 - PubMed
  7. Lancet. 2009 Aug 8;374(9688):477-90 - PubMed
  8. World J Gastroenterol. 2014 May 21;20(19):5679-84 - PubMed
  9. Gan To Kagaku Ryoho. 2010 Apr;37(4):582-6 - PubMed
  10. Clin Cancer Res. 2007 Jul 15;13(14):4154-63 - PubMed
  11. Fertil Steril. 1997 May;67(5):870-6 - PubMed
  12. Cancer Sci. 2013 Jan;104(1):1-8 - PubMed
  13. Methods. 2001 Dec;25(4):402-8 - PubMed
  14. PLoS One. 2011;6(9):e24897 - PubMed
  15. J Clin Endocrinol Metab. 2002 Jan;87(1):245-54 - PubMed
  16. Oncogene. 2000 Sep 7;19(38):4432-6 - PubMed
  17. World J Gastroenterol. 2011 Jan 21;17(3):290-9 - PubMed
  18. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 - PubMed
  19. J Clin Invest. 1989 Sep;84(3):829-39 - PubMed
  20. World J Gastrointest Oncol. 2012 Jul 15;4(7):156-69 - PubMed
  21. J Pathol. 2010 Nov;222(3):299-309 - PubMed
  22. Endocrinology. 2002 Sep;143(9):3259-67 - PubMed
  23. Gastric Cancer. 2005;8(2):86-94 - PubMed
  24. Nature. 1994 Jun 2;369(6479):414-8 - PubMed
  25. J Endocrinol. 2002 Oct;175(1):19-31 - PubMed
  26. Pathologe. 2010 Sep;31(5):331-2 - PubMed
  27. Mol Cell Endocrinol. 2001 Mar 28;174(1-2):121-7 - PubMed
  28. J Clin Oncol. 2005 Oct 10;23(29):7286-95 - PubMed
  29. Oncogene. 2002 Nov 28;21(54):8240-50 - PubMed
  30. Cell Signal. 2010 Jul;22(7):1033-43 - PubMed
  31. Endocr Rev. 2002 Dec;23(6):824-54 - PubMed
  32. J Cell Physiol. 2002 Jan;190(1):92-100 - PubMed
  33. Endocrinology. 1990 Jun;126(6):3033-42 - PubMed
  34. J Biol Chem. 1992 Jun 25;267(18):12692-9 - PubMed
  35. PLoS One. 2013;8(1):e54671 - PubMed
  36. Cancer Res. 2004 Apr 1;64(7):2397-405 - PubMed
  37. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  38. J Cell Physiol. 2003 Oct;197(1):131-8 - PubMed
  39. Cell Growth Differ. 1995 Mar;6(3):263-9 - PubMed
  40. Endocrinology. 2004 Jul;145(7):3369-74 - PubMed
  41. Mol Endocrinol. 1989 Nov;3(11):1701-9 - PubMed
  42. J Endocrinol. 1996 Jun;149(3):367-72 - PubMed
  43. Cancer Res. 2002 Jan 1;62(1):233-40 - PubMed
  44. Endocrinology. 1994 Nov;135(5):2168-76 - PubMed
  45. Growth Horm IGF Res. 2005 Jun;15(3):185-92 - PubMed
  46. Horm Metab Res. 1999 Feb-Mar;31(2-3):226-34 - PubMed
  47. Physiol Rev. 1996 Oct;76(4):1005-26 - PubMed
  48. Ann Intern Med. 1995 Jan 1;122(1):54-9 - PubMed
  49. PLoS One. 2012;7(8):e43555 - PubMed

Publication Types